<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02215824</url>
  </required_header>
  <id_info>
    <org_study_id>1181.1</org_study_id>
    <nct_id>NCT02215824</nct_id>
  </id_info>
  <brief_title>Investigation of Safety, Pharmacokinetics and Pharmacodynamics of Different Doses of BIWH 3 in Patients With Chronic Critical Limb Ischaemia</brief_title>
  <acronym>COINART-1</acronym>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Dose Escalation Study to Investigate Safety, Pharmacokinetics and Pharmacodynamics of Different Doses (0.2, 0.6, 2.0, 6.0, and 20.0 Î¼g/hr) of BIWH 3 Administered for 6 Hours in Patients With Chronic Critical Limb Ischaemia (CLI, Fontaine Class III or IV). COINART-1 Trial (First COllateral INto ARTery Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary aim of this trial was to investigate the safety of a 6 hour intraarterial
      infusion of BIWH 3 (pyro-Glu-rhMCP-1) in patients with severe peripheral arterial occlusive
      disease (PAOD) and chronic Critical Limb Ischaemia (Fontaine class III or IV).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>October 2002</start_date>
  <primary_completion_date type="Actual">October 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 180 days after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with clinically relevant changes in vital signs (heart rate, blood pressure, body temperature)</measure>
    <time_frame>baseline, up to 180 days after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with clinically relevant changes in laboratory evaluations</measure>
    <time_frame>baseline, up to 180 days after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with clinically relevant changes in 12- lead electrocardiogram (ECG)</measure>
    <time_frame>baseline, up to 180 days after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with clinically relevant changes in markers of inflammation</measure>
    <time_frame>baseline, up to 180 days after drug administration</time_frame>
    <description>measured by C-reactive Protein (CRP) and erythrocyte sedimentation rate (ESR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with clinically relevant changes in ophthalmic examinations</measure>
    <time_frame>baseline, up to 180 days after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with changes from baseline in progression of atherosclerosis</measure>
    <time_frame>day 180</time_frame>
    <description>measured by carotid duplex imaging</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with changes in local disease defined by degree of stenosis</measure>
    <time_frame>up to 6 months post treatment</time_frame>
    <description>assessed by magnetic resonance angiography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with changes from baseline in result of cancer screening</measure>
    <time_frame>day 180</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients developing an antibody response to BIWH 3</measure>
    <time_frame>baseline, up to 180 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in transcutaneous oxygen pressure (tcPO2)</measure>
    <time_frame>baseline, up to 180 days after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in lower extremity magnetic resonance angiography (MRA)</measure>
    <time_frame>baseline, up to 180 days after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ankle brachial or toe brachial index</measure>
    <time_frame>baseline, up to 180 days after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of amputations</measure>
    <time_frame>up to 180 days after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of ulcer healing</measure>
    <time_frame>up to 180 days after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline on visual analogue scale assessment of pain at rest</measure>
    <time_frame>up to 180 days after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BIWH 3 plasma concentration</measure>
    <time_frame>up to 180 days after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Mac-1 positive staining monocytes</measure>
    <time_frame>up to 180 days after drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>BIWH 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>in escalating doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIWH 3</intervention_name>
    <arm_group_label>BIWH 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  Patient must have severe PAOD with Chronic Critical Limb Ischaemia, Fontaine class III
             (ischaemic pain at rest) or IV (tissue ulceration or gangrene) due to atherosclerotic
             disease

          -  Patient must be &gt;= 18 years of age

          -  Patient must give written informed consent

          -  Patient must have a life expectancy of at least six months

        Exclusion:

          -  Transient ischaemic attack (TIA), cerebral vascular accident (CVA), myocardial
             infarction (MI) or episode of unstable angina within the past two months

          -  Ophthalmologic conditions: moderate to severe nonproliferative retinopathy,
             proliferative retinopathy, age related maculopathy with choroidal neovascularisation,
             macular edema, intraocular surgery within the previous 6 months, retinal vein
             occlusion

          -  Presence of a clinically significant disease which in the opinion of the investigator
             may either put the patient at risk because of participation in the study or a disease
             which may influence the result of the study or the patient's ability to participate in
             the study

          -  ECG results outside of the reference range of clinical relevance including, but not
             limited to QTcB &gt; 480 msec, PR interval &gt; 240 msec, QRS interval &gt; 140 msec

          -  History of malignant disease, or a positive result on any of the required cancer
             screening tests, unless a definitive subsequent evaluation for cancer is determined to
             be negative

          -  Patients at increased risk of colorectal cancer, including any of the following (1)
             colorectal cancer pr polyps in a first-degree relative younger than 60 or in two
             first-degree relatives of any age, (2) family history of familial adenomatous
             polyposis or hereditary non-polyposis colon cancer, (3) history of adenomatous polyps,
             or (4) history of chronic inflammatory bowel disease (chronic ulcerative colitis or
             Crohn's disease)

          -  Abnormalities greater than two times the upper limit of normal in any of the following
             laboratory values at Visit 1: alanine-aminotransferase (ALT),
             aspartate-aminotransferase (AST), gamma-glutamyl transferase (GGT), alkaline
             phosphatase or lactic dehydrogenase (LDH); abnormalities greater than 1.5 times the
             upper limit of normal of total bilirubin or white blood cell count

          -  Any concurrent infectious disease requiring treatment

          -  Severe renal insufficiency (estimated creatinine clearance &lt; 30 mL/min)

          -  Duffy antigen negative blood type with co-existing moderate to severe renal
             insufficiency (estimated creatinine clearance &lt; 80 mL/min), to avoid potential risk of
             significant increase of monocyte chemoattractant protein-1 (MCP-1) levels

          -  Known glomerulonephritis, even if creatinine clearance is apparently normal

          -  Thrombocytopenia, i.e. platelet count &lt;100,000 cells/Î¼l at Visit 1

          -  History of drug or alcohol abuse within the past 2 two years or active drug or alcohol
             abuse, present alcohol intake more than three drinks per day

          -  Inability to comply with the protocol

          -  Treatment with an investigational drug within 30 days or 5 half-lives, whichever is
             greater before Visit 2

          -  Use of cilostazol if cilostazol therapy was started within 2 months prior to trial
             enrollment, or planned initiation of cilostazol therapy during the trial period.
             Patients who have been on cilostazol for &gt; 2 months prior to enrollment may be
             enrolled

          -  Inability to discontinue the intake of coumadin until after completion of the
             treatment period. Patients who were on coumadin must have an international normalised
             ratio (INR) &lt; 1.8 at Visit 2

          -  Previous enrollment in this trial

          -  Hypersensitivity or allergy to heparin, conventional angiographic contrast dye, or
             magnetic resonance angiography (MRA) contrast

          -  Inability to undergo MRA (e.g. heart pacemaker, artificial heart valve, implanted
             neurostimulator, intrauterine device (IUD), metallic ear implant, implanted port for
             delivering insulin, or other foreign or implanted or metallic objects such as bullet
             fragments, metal plates, pins, screws or staples, joint replacement, or penile
             implant)

          -  Know HIV-infection

          -  Unwillingness to take blood products

          -  Pregnancy (to be excluded by serum and urine beta-human chorionic gonadotropin-test in
             women of childbearing potential) or breast feeding

          -  Female of childbearing potential (not 12 months post-menopausal or surgically
             sterilized) not using one of the following methods of birth control: hormonal
             contraceptives, oral or injectable/implantable
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2014</study_first_submitted>
  <study_first_submitted_qc>August 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2014</study_first_posted>
  <last_update_submitted>August 21, 2014</last_update_submitted>
  <last_update_submitted_qc>August 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

